
Dr. Bonebrake 9 Registrations
Dr. Williams 8 Registrations
Dr. Ellis & Dr Raju 7 Registrations each
Dr. Cunningham 6 Registrations
Dr. Goodwin & Dr. Nair 5 Registrations each

The month of December brought 12 new enrollments for CRO. Currently, we have 58.6 treatment credits and need to have 70 treatment credits to meet or NCI target goal of 120 for this grant year. Our cancer control credits are at 32.4 and need to be at 34.6 and we need to be at 40.8 to be on track to meet NCI goal. If you have suggestions to assist us to increase our enrollments to clinical trials please, let us know.

Study Profile for January
MDA 2008-0005  Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer is our profile study this month. This study is individuals with metastatic colorectal cancer who are scheduled to receive Irinotecan alone or in combination with 5-FU, Cetuximab, or other biologics, including Avastin. Any number or type of prior treatment regimens for metastatic disease is allowed. Patients must have adequate liver function and kidney function to qualify. Each enrollment is worth 1 cancer control credit for CRO.

Affiliate - Central Cares PA
Central Cares enrolled their first patient to E5103 on Tuesday, December 21st. YEA! Congratulations to Dr. Leo Shunyakov, Kim Wallin RN and Jill Gruber RN.

CRO Drugs Coming to CRO Administrative Office
CRO has communicated with NCI’s Pharmaceutical Management Branch (PMB) and are following their directions with moving CRO research drugs to the CRO Administrative Office. CRO’s Executive Committee met on Monday, December 16th and approved moving the CRO research drugs from Convenient Care Pharmacy to the CRO Administrative Office. Equipment to remotely monitor the drug refrigerator is in process at this time. We are hopeful this transfer will be completed in the next couple of months.

March 28th Steering Committee Meeting
Tanios Behaii-Saab, Assistant Professor at Ohio State University James Cancer Hospital and Solove Research Institute will be speaking on Avastin for colorectal cancer and Herceptin for gastric cancer. This CRO Steering meeting will be on March 28th, 2011 at 6PM Touch Restaurant. Tim England with Genentech BioOncology is assisting with sponsoring this event. Please plan to attend.
New Studies Approved in December 2010

**SWOG S0933**  Phase II Study of RO4929097 (NSC-749225) In Advanced Melanoma – Cox only

**MDA 2008-0005**  Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer – Reopened Cox only

Studies Closed December 2010:

**MDA 00-156**  A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer

**GOG 0248**  A Randomized Phase II Trial of Temsirolimus or the Combination of Hormonal Therapy Plus Temsirolimus in Women with Advanced or Recurrent Endometrial Carcinoma

**SWOG S0309**  Myeloma Specimen Repository Protocol, Ancillary

**SWOG S0600**  Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progress on Bevacizumab with Either FOLFOX, OPTIMOX, OR XELOX